Palbociclib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-PALBOCICLIB |
|---|---|
| Type | Drug |
| Aliases | IbranceПалбоцикліб |
| Status | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Drug Facts
| Class | CDK4/6 inhibitor |
|---|---|
| Mechanism | Selective inhibitor of cyclin-dependent kinases 4 and 6 — blocks Rb phosphorylation, arresting cells in G1. Combined with endocrine therapy in HR+/HER2- metastatic; modest adjuvant benefit (PALLAS / PENELOPE-B negative). |
| Typical dosing | 125 mg PO once daily, days 1-21 of 28-day cycle (3 weeks on, 1 week off). Combined with AI (1L) or fulvestrant (2L+). |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Workhorse CDK4/6i for HR+/HER2- metastatic 1L (PALOMA-1/2) and 2L (PALOMA-3). PFS benefit clear; OS less consistent vs ribociclib. Adjuvant data negative — not used in early breast.
Used By
Regimens
REG-AI-PALBOCICLIB- AI + palbociclib (HR+/HER2- metastatic 1L)REG-INAVOLISIB-PALBO-FULV-BREAST- Inavolisib + palbociclib + fulvestrant (HR+/HER2- PIK3CA-mutant 1L metastatic post-adjuva...